Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and …

NJ Bahlis, P Moreau, H Nahi, T Plesner, H Goldschmidt… - 2017 - ascopubs.org
8025 Background: Daratumumab (D) is a human CD38-targeting mAb that significantly
prolongs progression-free survival (PFS) when added to standard-of-care regimens in …
被引用次数：23 相关文章

[引用][C] DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY …

NJ Bahlis, P Moreau, H Nahi, T Plesner… - Hematological …, 2017 - Wiley Online Library
Methods: Pts with≥ 1 prior line of therapy (LOT) received Rd (25 mg PO lenalidomide on
days 1–21 of each q4w cycle; 40 mg dexamethasone weekly)±D (16 mg/kg IV qw for cycles …